Publications by authors named "Caroline Pot Kreis"
[Neurology: what's new in 2023].
Rev Med Suisse
January 2024
Article Synopsis
- In 2023, lecanemab was introduced as a new treatment for Alzheimer's disease, showcasing advancements in Alzheimer's care.
- New biomarkers have significantly improved the diagnosis and monitoring of conditions like peripheral neuropathies and synucleinopathies.
- Research has unveiled the impact of genetic factors in multiple sclerosis progression, while new migraine treatments and expanded thrombectomy criteria are enhancing patient care in neurology.
The year 2022 was marked by the development of numerous new treatments for refractory myasthenia gravis. The link between epilepsy and cerebrovascular disorder was studied and lamotrigine discovered to be the optimal treatment choice for epilepsy secondary to stroke to prevent mortality on patient of 45 years and older. New randomized study finally demonstrated the utility of thrombectomy in selected patients with basilar artery occlusion.
View Article and Find Full Text PDF[Neurology : what's new in 2021].
Rev Med Suisse
January 2022
In 2021, we assisted to the publication of new diagnostic criteria, classifications, and guidelines (CIDP, brain tumors, auto-immune encephalitis). Several studies helped to define the pharmacological management of focal and generalized epileptic seizures and epilepsy in pregnant women. The availability of biomarkers and the approval of immunotherapies are modifying the landscape of dementia management.
View Article and Find Full Text PDFArticle Synopsis
- In 2020, significant advancements were made in blood biomarkers for Alzheimer's disease, improving diagnosis and management.
- New research focused on the treatment of status epilepticus and epilepsy, especially in women of childbearing age, alongside updated Swiss guidelines for acute stroke management and prevention.
- Progress was noted in managing NeuroMyelitis Optica Spectrum Disorder (NMO-SD), neurological presentations related to COVID-19, new treatments for migraines, and pharmacological therapies for Parkinson's disease.
Objective: In a previous pilot monocentric study, we investigated the relation between human leukocyte antigen (HLA) genotype and multiple sclerosis (MS) disease progression over 2 years. HLA-A*02 allele was correlated with better outcomes, whereas HLA-B*07 and HLA-B*44 were correlated with worse outcomes. The objective of this extension study was to further investigate the possible association of HLA genotype with disease status and progression in MS as measured by sensitive and complex clinical and imaging parameters.
View Article and Find Full Text PDF